Bellerophon Therapeutics

Bellerophon Therapeutics: announces exit or restructuring costs, reports an executive or board change and discloses other events

Form
8-K
Filed
Period
Importance
Major
Document
8-K
  • Announces exit or restructuring costs (2.05)
  • Reports an executive or board change (5.02)
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

Get an email when Bellerophon Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.